1. Home
  2. CLPS vs RNTX Comparison

CLPS vs RNTX Comparison

Compare CLPS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

N/A

Current Price

$1.18

Market Cap

36.0M

Sector

Technology

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
RNTX
Founded
2005
2001
Country
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
30.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CLPS
RNTX
Price
$1.18
$1.13
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
21.7K
114.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
11.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.02
52 Week High
$1.88
$2.96

Technical Indicators

Market Signals
Indicator
CLPS
RNTX
Relative Strength Index (RSI) 68.80 40.27
Support Level $1.18 $1.08
Resistance Level $1.23 $1.21
Average True Range (ATR) 0.05 0.11
MACD 0.00 -0.01
Stochastic Oscillator 72.73 11.36

Price Performance

Historical Comparison
CLPS
RNTX

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: